ArticleESMO open2024

Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing.

T Takeshita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.